KRT19

(redirected from CK19)

KRT19

A gene on chromosome 17q21.2 that encodes the smallest of all type-I keratin proteins, which is expressed in the periderm, the transiently superficial layer that surrounds the developing epidermis.
References in periodicals archive ?
Use Annexin A8 SantaC (a) Sc-28825 RUO CA19-9 CellMq (b) 399M-15 IVD CEA Biogx (c) MU009-UC IVD CDX-2 CellMq (b) 235R-15 IVD Claudin 18 Invitro (d) 38-8100 ASR Claudin 4 Invitro (d) 32-9400 ASR CK17 DAKO (e) M7046 IVD CK19 Ventana (f) 760-4281 IVD CK20 CellMq (b) 320M-15 IVD CK7 CellMq (b) 307M-95 IVD CAM 5.
In breast cancer, the mRNA expression of CEA, CK19, CK20, GA733.
CTCs and is based on cultured viable cells releasing CK19 as marker for tumor cells, including colon cancer cells (10).
Remaining slices of node are sent for histology, including CK19 immunohistochemistry at multiple levels.
3) Special techniques such as Ki-67 staining and immunohistochemistry studies for cytokeratin subtypes CK8, CK7, and CK19 might guide in pathologically differentiating SNUC from nasopharyngeal carcinoma and squamous cell carcinoma.
Metastatic breast cancer cells also express CK19, a biomarker that is of high sensitivity but limited specificity for breast cancers (10).
Quantitative RT-PCR assay for CK19 consisted of RNA Hybridization Probes 5x buffer (Roche Diagnostics), RT-PCR enzyme mix, 1.
The Trust has a requirement to procure a semi-automated system to perform an assay to determine the presence of micro and macro metastases for the Cellular Pathology department and the associated breast surgery team (Intra operative sentinel node assay unit automated PCR or similar for CK19 mRNA).
6] Nonstandard abbreviations: HER2, human epidermal growth factor receptor 2; OS, overall survival; CTC, circulating tumor cells; FDA, Food and Drug Administration; MBC, metastatic breast cancer; DTC, disseminated tumor cells; LCCRH, Laboratory of Rare Circulating Human Cells; CK19, cytokeratin-19; PFS, progression-free survival; BIC, Bayesian information criterion; EMT, epithelial-mesenchymal transition.
Tumour cells demonstrated immunopositivity for pancytokeratin, vimentin, CD10, CK19 and AMACR (Fig.
TCC are immunohistochemically reactive for CD10, AMACR (P504-S), CK8, CK18, and CK19 (3, 6).